Real-World Evidence (FLEX Study)
Early-Stage Breast Cancer
Observational StudyActive
Key Facts
About Agendia
Agendia is a commercial-stage diagnostics company specializing in genomic profiling for early-stage breast cancer. Its core offerings, MammaPrint and BluePrint, analyze tumor biology from a single sample to predict recurrence risk and identify molecular subtypes, aiming to personalize treatment and reduce both under- and over-treatment. Founded in 2005 and headquartered in Amsterdam, the company serves a global market, with its tests supported by extensive clinical validation and inclusion in major oncology guidelines. Agendia operates as a private company, generating revenue from its diagnostic testing services.
View full company profileTherapeutic Areas
Other Early-Stage Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| MammaPrint/BluePrint Clinical Utility Expansion | Agendia | Commercial |
| OncoTect for Taxanes in Early-Stage Breast Cancer | Aida Oncology | Clinical Validation |
| Pathlight MRD Test | SAGA Diagnostics | Commercial |
| GammaPod Commercialization & Clinical Adoption | Xcision Medical Systems | Commercial |
| Signatera™ MRD (Adjuvant De-escalation) | Natera | Clinical Utility Study |